- Email: [email protected]
ADA—AMERICA'S DENTAL MEETING
NEWS
ANTIDEPRESSANTS MAY BE LINKED TO IMPLANT FAILURE RISK, RESEARCHERS REPORT
S
elective serotonin reuptake inhibitors (SSRIs)—the most widely used antidepressant drugs— may be associated with an increased risk of failure of osseointegrated implants, according to a study published online Sept. 3 in Journal of Dental Research. Researchers from McGill University in Montreal, Quebec, Canada, and East Coast Oral Surgery in Moncton, New Brunswick, Canada, conducted a retrospective cohort study of patients treated with dental implants. The researchers examined records from 490 patients who received a total of 916 implants from January 2007 to January 2013. Eight hundred twenty-two of these implants were placed in 440 patients who did not use SSRIs, and 94 implants were placed in 50 patients who used SSRIs, the authors wrote. After three to 67 months’ followup, the researchers found that 38 of 822 implants in the nonusers group had failed, for a failure rate of 4.6 percent. In the users group, 10 of 94 implants had failed, for a failure rate of 10.6 percent. The researchers also reported that small implant diameters, bone augmentation and smoking habits seemed to be associated with a
1016
JADA 145(10) http://jada.ada.org
higher risk of implant failure. One study limitation was that the investigators could not acquire information about drug compliance dose and treatment period from patients’ files, the authors wrote. This study was supported by the China Scholarship Council, Clifford Wong Fellowship, Canadian Institutes of Health Research, Institute of Musculoskeletal Health and Arthritis Bridge Funding, and the Network for Oral and Bone Health Research. COST-EFFECTIVE PROCEDURE FOR TRIGEMINAL NEURALGIA UNDERUSED, STUDY FINDS
T
he most cost-effective surgical procedure for trigeminal neuralgia may be the one performed least often, according to a study published in the September issue of Neurosurgery. Siviero Agazzi, MD, MBA, and colleagues from the University of South Florida in Tampa compared the cost-effectiveness of various surgical options for trigeminal neuralgia by analyzing Medicare claims data during 2011. Of 1,582 patients with trigeminal neuralgia, 94 (6 percent) underwent surgical treatment, the authors wrote. Forty-eight of these patients underwent microvascular decompression (MVD), 39 underwent stereotactic radiosurgery (SRS) and seven underwent percutaneous
October 2014
stereotaxic rhizotomy (PSR). The researchers reported that the average weighted cost of surgery was about $40,000 for MVD, $38,000 for SRS and $3,900 for PSR. Over 10 years, the average qualityadjusted life-years (QALYs)—reflecting the time free of pain without medications—were 8.2 for patients undergoing MVD, 4.9 for those undergoing SRS and 6.5 for those undergoing PSR, the authors wrote. After accounting for these differences, the researchers found that PSR was the most cost-effective option. The reported cost per QALY gained was about $600 for PSR, $4,900 for MVD and $7,800 for SRS. Dr. Agazzi and coauthors emphasized the preliminary nature of their study. However, the results suggest that PSR is an underutilized procedure for patients with trigeminal neuralgia who require surgery, wrote the authors. ■ Compiled by Janice Snider, senior editor.
CALENDAR OF EVENTS ADA—AMERICA’S DENTAL MEETING
2015 Nov. 5-10, Washington 2016 Oct. 20-25, Denver 2017 Oct. 19-24, Atlanta
ANTIDEPRESSANTS MAY BE LINKED TO IMPLANT FAILURE RISK, RESEARCHERS REPORT
S
elective serotonin reuptake inhibitors (SSRIs)—the most widely used antidepressant drugs— may be associated with an increased risk of failure of osseointegrated implants, according to a study published online Sept. 3 in Journal of Dental Research. Researchers from McGill University in Montreal, Quebec, Canada, and East Coast Oral Surgery in Moncton, New Brunswick, Canada, conducted a retrospective cohort study of patients treated with dental implants. The researchers examined records from 490 patients who received a total of 916 implants from January 2007 to January 2013. Eight hundred twenty-two of these implants were placed in 440 patients who did not use SSRIs, and 94 implants were placed in 50 patients who used SSRIs, the authors wrote. After three to 67 months’ followup, the researchers found that 38 of 822 implants in the nonusers group had failed, for a failure rate of 4.6 percent. In the users group, 10 of 94 implants had failed, for a failure rate of 10.6 percent. The researchers also reported that small implant diameters, bone augmentation and smoking habits seemed to be associated with a
1016
JADA 145(10) http://jada.ada.org
higher risk of implant failure. One study limitation was that the investigators could not acquire information about drug compliance dose and treatment period from patients’ files, the authors wrote. This study was supported by the China Scholarship Council, Clifford Wong Fellowship, Canadian Institutes of Health Research, Institute of Musculoskeletal Health and Arthritis Bridge Funding, and the Network for Oral and Bone Health Research. COST-EFFECTIVE PROCEDURE FOR TRIGEMINAL NEURALGIA UNDERUSED, STUDY FINDS
T
he most cost-effective surgical procedure for trigeminal neuralgia may be the one performed least often, according to a study published in the September issue of Neurosurgery. Siviero Agazzi, MD, MBA, and colleagues from the University of South Florida in Tampa compared the cost-effectiveness of various surgical options for trigeminal neuralgia by analyzing Medicare claims data during 2011. Of 1,582 patients with trigeminal neuralgia, 94 (6 percent) underwent surgical treatment, the authors wrote. Forty-eight of these patients underwent microvascular decompression (MVD), 39 underwent stereotactic radiosurgery (SRS) and seven underwent percutaneous
October 2014
stereotaxic rhizotomy (PSR). The researchers reported that the average weighted cost of surgery was about $40,000 for MVD, $38,000 for SRS and $3,900 for PSR. Over 10 years, the average qualityadjusted life-years (QALYs)—reflecting the time free of pain without medications—were 8.2 for patients undergoing MVD, 4.9 for those undergoing SRS and 6.5 for those undergoing PSR, the authors wrote. After accounting for these differences, the researchers found that PSR was the most cost-effective option. The reported cost per QALY gained was about $600 for PSR, $4,900 for MVD and $7,800 for SRS. Dr. Agazzi and coauthors emphasized the preliminary nature of their study. However, the results suggest that PSR is an underutilized procedure for patients with trigeminal neuralgia who require surgery, wrote the authors. ■ Compiled by Janice Snider, senior editor.
CALENDAR OF EVENTS ADA—AMERICA’S DENTAL MEETING
2015 Nov. 5-10, Washington 2016 Oct. 20-25, Denver 2017 Oct. 19-24, Atlanta